Growth portfolio revenue rose 12% year over year to $7.7 billion.
Eight growth portfolio medicines annualized over $1 billion each.
Full-year 2026 adjusted EPS guidance was $6.35 to $6.55.
On its third-quarter 2026 earnings call, held on Oct. 29, 2026, Bristol-Myers Squibb (NYSE:BMY) announced an increase to its full-year earnings guidance as expanding sales across new medicines offset generic competition on older treatments. The drugmaker is building a broader commercial base to absorb upcoming loss of exclusivity (LOE), or patent expiration, on major therapies while advancing its drug development pipeline.
Management offers three takeaways on how the strategy is unfolding.
The company expanded revenue in its growth portfolio by 12% year over year to $7.7 billion during the quarter. Diversifying revenue across multiple blockbuster drugs helps replace sales lost as older therapies face generic competition.
First, sustaining the momentum across our growth portfolio. We now have 8 growth portfolio medicines, each annualizing over $1 billion based on Q3 sales, giving us a broad base of growth drivers.
-- Christopher S. Boerner, Board Chair and Chief Executive Officer
Management advanced four registrational late-stage clinical trials over two months across oncology and rare lung diseases. The accelerated Food and Drug Administration (FDA) clearance of Symvexis, an oral therapy for multiple myeloma, establishes a new revenue driver in blood cancer care.
The momentum in our late stage pipeline has accelerated. In the past 2 months alone, we announced positive data for 4 registrational studies.
-- Christopher S. Boerner, Board Chair and Chief Executive Officer
A strategic productivity initiative is driving $2 billion in cost savings to protect operating margins as legacy drug sales decline. Management generated $4.2 billion in operating cash flow during the quarter while raising full-year adjusted earnings per share (EPS) guidance.
Our third quarter results reflect continued strong execution of our growth portfolio and continued strength from Eliquis. We remain focused on financial discipline, balancing investments in our growth drivers with continued productivity improvements.
-- David V. Elkins, Chief Financial Officer
Commercial execution is accelerating across new therapeutic launches, and management isn't hiding its satisfaction with the momentum. The company is leaning on proprietary manufacturing sites, pipeline execution, and cost discipline to secure future cash flows.
Taken together, we are entering the final quarter of the year with real momentum. Our growth portfolio is performing well, We are advancing our pipeline with meaningful wins and remain highly disciplined in ensuring our cost structure is aligned with our revenue base.
-- Christopher S. Boerner, Board Chair and Chief Executive Officer
The business faces an estimated $1.5 billion to $2 billion revenue step-down in 2027 from European patent expirations on blood thinner Eliquis. Even so, internal manufacturing investments and active drug development create a resilient platform for long-term shareholder value.
As we continue to execute, we are well positioned to deliver long term durable growth into the next decade.
-- Christopher S. Boerner, Board Chair and Chief Executive Officer
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*
Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 18, 2026.
The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.